Innovotech Announces New Chairman and Grant of Stock Options

Innovotech Inc. (TSX VENTURE:IOT) ("Innovotech") today announces that Dr.
Wolfgang Muhs has resigned as the Chairman of the Board of Innovotech and Kerry
Brown has been elected as the new Chairman of the Board. At the Annual General
Meeting held on April 30, 2013 all of management's nominees were elected to the
Board of Directors. The Board members of Innovotech are Kerry Brown CA, Dr.
Gerard Tertzakian, Dr. Wolfgang Muhs, Dr. James Timourian, Bruce Hirsche Q.C.,
Dr. Lorne Babiuk and Bernard Grobbelaar, CA (and CA (SA)). 


In accordance with the policies of the TSX Venture Exchange, the Board of
Directors has approved a grant of stock options to directors and employees of
Innovotech to purchase an aggregate of 106,000 common shares pursuant to its
stock option plan. These options have an exercise price of $0.30 per common
share and expire on May 14, 2023.


About Innovotech Inc.:

Innovotech Inc. is a pioneer in the field of biofilm product development,
focused on providing innovative and practical solutions to medical, agricultural
and industrial problems caused by microbial biofilms. Biofilms are organized
communities of microorganisms that exist in virtually every natural environment
and are responsible for a host of diseases in human health, animal health and
agriculture. There are few products or regulatory standards, aside from those of
Innovotech, designed specifically for biofilm-forming organisms.


Innovotech has a broad range of products that address the issue of biofilms
within a number of different industries, including commercially available
products in a variety of market segments; the MBEC Assay(TM), InnovoSIL(TM),
bioFILM PA(TM), InnovoSCEPT-Human and InnovoSCEPT-Veterinary kits. The MBEC
Assay(TM) is a high throughput biofilm growth device that was recently approved
as an ASTM International standard. InnovoSIL(TM) is a family of silver-based
antimicrobials promising superior performance for medical device coatings,
bioFILM PA(TM) and InnovoSCEPT-Human are the first diagnostic tests to assist
physicians in the selection of the most effective antibiotic treatment for
patients with biofilm-based chronic infections, while the InnovoSCEPT veterinary
tests are designed to determine the most effective antibiotic treatment for
infections for chronic infections in both large and small animals. Agress(R) and
AgreGuard(TM) are unique, environmentally friendly seed treatments and plan
sprays designed to protect crops against both bacterial and fungal infections.
Agress(R) is entering the regulatory approval stage.


Connect with us: 

Website: www.innovotech.ca 

Blog: www.cf-test.ca 

Twitter: www.twitter.com/innovotech 

Facebook: www.facebook.com/innovotech 

FOR FURTHER INFORMATION PLEASE CONTACT: 
Innovotech Inc.
Ken Boutilier
President and CEO
[phone] ext. 221
[phone] (FAX)
[e-mail]